Showing 8401-8410 of 8692 results for "".
- Lithera Announces Appointment of Dr. Lincoln Krochmal as Chief Medical Officerhttps://practicaldermatology.com/news/20131121-lithera_announces_appointment_of_dr_lincoln_krochmal_as_chief_medical_officer/2459407/Lincoln Krochmal, MD was recently appointed as Chief Medical Officer of Lithera, Inc. According to the company, this appointment reflects the company's continued growth as it prepares to enter la
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- Actelion Launches Valchlor to Treat Stage IA and IB Mycosis Fungoides-type Cutaneous T-cell Lymphomahttps://practicaldermatology.com/news/20131119-actelion_launches_valchlor_to_treat_stage_ia_and_ib_mycosis_fungoides-type_cutaneous_t-cell_lymphoma/2459409/The FDA approved Actelion's Valchlor (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine. Valchlor, a gel that is applied topically once a day, is an alkylating drug indicated to treat p
- Antares Pharma Enters into Promotion and Marketing Agreement with LEO Pharma for Otrexuphttps://practicaldermatology.com/news/20131118-antares_pharma_enters_into_promotion_and_marketing_agreement_with_leo_pharma_for_otrexup/2459413/Antares Pharma, Inc. announced an exclusive agreement with LEO Pharma for the promotion and marketing of Otrexup (methotrexate) to dermatologists for symptomatic c
- Valeant's Antifungal Agent Luzu Wins FDA Approvalhttps://practicaldermatology.com/news/20131115-valeants_antifungal_luzu_wins_fda_approval/2459414/The FDA has approved Luzu® (luliconazole, Valeant) Cream, 1% for the topical treatment of athlete's foot (interdigital tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and olde
- Myriad Genetics Launches myPath Melanoma Diagnostic Testhttps://practicaldermatology.com/news/20131114-myriad_genetics_launches_mypath_melanoma_diagnostic_test/2459416/
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Merz Pharma Group Acquires Anteis S.A.https://practicaldermatology.com/news/20131112-merz_pharma_group_acquires_anteis_sa/2459418/
- Cosmetic Surgery Forum Announces Innovators in Dermatology Recipientshttps://practicaldermatology.com/news/20131107-cosmetic_surgery_forum_announces_innovators_in_dermatology_recipients/2459420/The upcoming Cosmetic Surgery Forum (www.cosmeticsurgeryforum.com), taking place at the ARIA Resort and Casino in Las Vegas from December 5-7, recently announced the recipients of its “Innovators in Dermatology” presentation. Among those honored this year will be Jim Hartman, Vice President of US Ae
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that